Etofibrate
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 2-[(pyridin-3-yl)carbonyloxy]ethyl 2-(4-chlorophenoxy)-2-methylpropanoate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Metabolism | Hydrolyzed to clofibric acid and niacin |
| Identifiers | |
| CAS number | 31637-97-5 |
| ATC code | C10AB09 |
| PubChem | CID 65777 |
| ChemSpider | 59197  |
| UNII | 23TF67G79M |
| KEGG | D07187 |
| ChEMBL | CHEMBL358150 |
| Chemical data | |
| Formula | C18H18ClNO5 |
| Mol. mass | 363.792 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.[1]
[edit] References
- ^ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res 34 (2): 177–82. doi:10.1590/S0100-879X2001000200004. PMID 11175492. Free full text
|
||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
